"Partial Nephrectomy with Veriset: A Renorrhaphy-Less Approach".

Area of Science:

• Urology
• Surgical Innovation
• Nephrology

Background:

• Renorrhaphy in partial nephrectomy is technically demanding, potentially increasing warm ischemia time (WIT).
• Exploring novel hemostatic agents is crucial for improving outcomes in robot-assisted partial nephrectomy (RAPN).

Purpose of the Study:

• To evaluate Veriset™ patch as an alternative to renorrhaphy in RAPN.
• To compare WIT, console time, and postoperative renal function between Veriset™ and conventional renorrhaphy.

Main Methods:

• Retrospective analysis of 86 patients undergoing RAPN, propensity score matched into Veriset™ (n=43) and renorrhaphy (n=43) groups.
• Data collected included demographics, tumor characteristics, intraoperative details, blood loss, complications, and 6-month follow-up.
• Key outcome measures were console time, WIT, and changes in estimated glomerular filtration rate (eGFR).

Main Results:

• The Veriset™ group showed significantly reduced console time (82.02 vs 95.53 min) and WIT (11.95 vs 17.63 min) (p<0.014 and p<0.001).
• Postoperative day 1 eGFR showed a significantly smaller decrease in the Veriset™ group (-0.21 vs -7.56 mL/min/1.73 m²; p=0.015).
• Hemostasis was achieved with Veriset™ in 93.03% of cases; blood loss, transfusion rates, and 6-month renal function were comparable between groups.

Conclusions:

• Veriset™ patch is a viable alternative to renorrhaphy in RAPN, leading to shorter WIT and console times.
• Early postoperative renal function is better preserved with Veriset™ application.
• Veriset™ offers comparable safety and efficacy to renorrhaphy, with potential benefits for renal function preservation.